The DIAMOND trial, a robust study evaluating potassium binders in the HF population with active or prior hyperkalemia, demonstrated that patiromer effectively controlled serum potassium levels, with a mean difference in potassium of approximately 0.10 mmol/L between the patiromer and placebo groups
Titration protocols therefore hold a dose until nausea and other gastrointestinal effects settle rather than escalating on a fixed target date
Weight Loss Goal: For patients with a high percentage of total body weight they need to lose, we may recommend starting with Tirzepatide to maximize initial momentum
Understanding your genetic profile helps clinicians personalize both your medication approach and dietary recommendations, moving beyond generic food lists to choices that match your biology
Some patients transition to microdose protocols or alternative compounds if they experience tolerability concerns
Do I have to follow a diet or exercise plan